Completed PHASE3 INTERVENTIONAL 1-arm NCT00335374

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Sponsor: Solvay Pharmaceuticals

Conditions Early Stage Parkinson's Disease

Interventions Pardoprunox

Updated 7 times since 2017 Last updated: Feb 5, 2009 Started: Aug 31, 2007 Primary completion: Sep 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Early Stage Parkinson's Disease, this trial is completed. The trial is conducted by Solvay Pharmaceuticals and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Solvay Pharmaceuticals

Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Augusta, United States , Bangalore, India , Bangkok, Thailand , Bedford Park, Australia , Birmingham, United States , Boca Raton, United States , Bochum, Germany , Boston, United States , Cape Town, South Africa and 57 more locations